# jRCT2080225166 (NCT04195750)

> A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04195750
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Carcinoma, Renal Cell
- Interventions: Belzutifan; Everolimus
- Enrollment: 755
- Primary outcome: Progression-free Survival (PFS) Per Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
- Primary outcome: Overall Survival (OS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=jrct2080225166-nct04195750